Effect of G-CSF on MDSC and Cancer Stem-cells Interactions in Non-small Cell Lung Cancers (CIRCUIT)

Launched by UNIVERSITY HOSPITAL, BORDEAUX · Nov 26, 2024

Keywords

ClinConnect Summary

The CIRCUIT trial is studying how a medication called Granulocyte Colony Stimulating Factor (G-CSF) affects certain cells in the blood of patients with non-small cell lung cancer (NSCLC). This type of cancer can be hard to treat because it has ways of hiding from the immune system, specifically using two types of cells: cancer stem cells and myeloid-derived suppressor cells. The trial aims to better understand how G-CSF might change the interaction between these cells and potentially improve treatment outcomes for patients receiving chemotherapy and immunotherapy.

To participate in this trial, you need to be at least 18 years old and have a confirmed diagnosis of lung adenocarcinoma that is advanced and cannot be treated with local therapies. You should also be receiving chemotherapy and immunotherapy as your first line of treatment. However, certain conditions may exclude you, such as having a different type of lung cancer or being pregnant. If you qualify, you'll be asked to sign a consent form, and then you can expect to provide a blood sample that will help researchers learn more about the effects of G-CSF on your cancer treatment. This trial is not yet recruiting participants, but it represents an important step in understanding and potentially improving cancer therapies.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients (male or female) aged ≥ 18 years
• • Histological or cytological proven lung adenocarcinoma, metastatic or locally advanced not accessible to local therapy
• • Receiving chemotherapy and immunotherapy as first-line treatment
• • Signed written informed consent (no later than the day of inclusion, and before the blood sample collection)
• • Patient affiliated or beneficiary to a health security system;
• Exclusion Criteria:
• • Patient with a small cell lung carcinoma
• • Non-metastatic disease
• • Actionable mutation or genomic alteration in EGFR, ALK or ROS1
• • Corticosteroids \> 10 mg/j
• • Autoimmune disease
• • Active and uncontrolled HIV infection
• • Concomitant cancer
• • Pregnancy or lactating women
• • Psychiatric or medical conditions that prohibit the understanding and rendering of informed consent
• • Patient under a legal protection measure
• • Patient with a deprived liberty condition
• • Patient incapable of giving signed informed consent
• • Patient within the exclusion period for another clinical trial, or participating to another interventional trial within 30 days before the beginning of this project